Atossa Therapeutics Q2 net loss widens to $18.1 million; reports no revenue - ATOS News | RalliesAtossa Therapeutics Q2 net loss widens to $18.1 million; reports no revenue
A
ATOS• Q2 and first-half results
- Atossa Therapeutics posted a GAAP net loss of USD 18.1 million for the six months ended June 30, 2026, using USD 19.23 million in operating cash flow.
- Operating expenses fell 3.33% to USD 8.7 million for the quarter, while they rose 12.73% to USD 18.6 million for the first half.
- R&D spending slipped 11% to USD 4.9 million for the quarter, while it was flat at USD 9.68 million for the first half.
- G&A expense rose 7% to USD 3.8 million for the quarter, climbing 31% to USD 8.89 million for the first half on higher legal fees.
- Cash and cash equivalents were USD 26.1 million at June 30, 2026; the company raised USD 4 million net in a June registered direct offering.
